Get the Stockscreener App
8.53
3.39%
+0.28
After Hours:
8.9121
0.3821
+4.48%
Compass Pathways Plc ADR stock is currently priced at $8.53, with a 24-hour trading volume of 519.11K.
It has seen a +3.39% increased in the last 24 hours and a -12.06% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $8.43 pivot point. If it approaches the $8.67 resistance level, significant changes may occur.
Previous Close:
$8.25
Open:
$8.6
24h Volume:
519.11K
Market Cap:
$582.96M
Revenue:
-
Net Income/Loss:
$-118.46M
P/E Ratio:
-3.6298
EPS:
-2.35
Net Cash Flow:
$-97.44M
1W Performance:
+7.43%
1M Performance:
-12.06%
6M Performance:
+33.07%
1Y Performance:
+8.94%
1D Range:
$8.47
$9.36
52W Range:
$5.01
$12.75
Compass Pathways Plc ADR Stock (CMPS) Company Profile
Name
Compass Pathways Plc ADR
Sector
Industry
Phone
44 64 6905 3974
Address
1 Ashley Road, 3rd Floor, Altrincham
Compass Pathways Plc ADR Stock (CMPS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-21-22 | Resumed | Berenberg | Buy |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Oct-29-21 | Initiated | Oppenheimer | Outperform |
| Jul-13-21 | Initiated | Citigroup | Buy |
| Jun-28-21 | Initiated | Maxim Group | Buy |
| May-11-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-01-21 | Initiated | ROTH Capital | Buy |
| Oct-14-20 | Initiated | H.C. Wainwright | Buy |
| Oct-13-20 | Initiated | Berenberg | Buy |
| Oct-13-20 | Initiated | Canaccord Genuity | Buy |
| Oct-13-20 | Initiated | Cowen | Outperform |
| Oct-13-20 | Initiated | Evercore ISI | Outperform |
View All
Compass Pathways Plc ADR Stock (CMPS) Latest News
Compass Pathways to announce first quarter financial results on May 8, 2024
GlobeNewswire Inc.
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
GlobeNewswire Inc.
Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression
GlobeNewswire Inc.
Compass Pathways to participate in upcoming 23rd Annual Needham Virtual Healthcare Conference
GlobeNewswire Inc.
Micron, Iris Energy, Trip.com Group And Other Big Stocks Moving Higher On Monday
Benzinga
Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors
GlobeNewswire Inc.
Compass Pathways Plc ADR Stock (CMPS) Financials Data
Compass Pathways Plc ADR (CMPS) Net Income 2024
CMPS net income (TTM) was -$118.46 million for the quarter ending December 31, 2023, a -29.46% decrease year-over-year.
Compass Pathways Plc ADR (CMPS) Cash Flow 2024
CMPS recorded a free cash flow (TTM) of -$97.44 million for the quarter ending December 31, 2023, a +8.11% increase year-over-year.
Compass Pathways Plc ADR (CMPS) Earnings per Share 2024
CMPS earnings per share (TTM) was -$2.3654 for the quarter ending December 31, 2023, a -9.51% decline year-over-year.
About Compass Pathways Plc ADR
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.
0.27%
0.29%
Cap:
|
Volume (24h):